Literature DB >> 17892369

Biomarkers for Alzheimer's disease.

Malcolm Ward1.   

Abstract

Alzheimer's disease (AD) is a horribly debilitating disease that will increase in prevalence as the populations of the USA and Europe continue to age. It is expected that the USA alone will see some 16 million cases by 2050. At present, there is no cure for the disease and early diagnosis is all but impossible. The onset of disease is not manifested clinically and little is known regarding the cause of nonfamiliar AD. There is a need for biomarkers associated with AD to aid the diagnosis of this disease and to detect progression. Especially needed are biomarkers to monitor the effect of new drugs and therapeutic strategies as they are developed. A biomarker may be a genetic trait, a biochemical change, such as a protein, peptide or metabolite, or a change in a structural or functional feature detected using imaging technology. This review aims to cover the important field of biomarker research in association with AD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17892369     DOI: 10.1586/14737159.7.5.635

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  6 in total

1.  Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology.

Authors:  Yoshiaki Sato; Ikumi Suzuki; Tatsuji Nakamura; Francois Bernier; Ken Aoshima; Yoshiya Oda
Journal:  J Lipid Res       Date:  2011-12-27       Impact factor: 5.922

2.  Estimating and disclosing the risk of developing Alzheimer's disease: challenges, controversies and future directions.

Authors:  J Scott Roberts; Sarah M Tersegno
Journal:  Future Neurol       Date:  2010-07-01

3.  The leaf ionome as a multivariable system to detect a plant's physiological status.

Authors:  Ivan R Baxter; Olga Vitek; Brett Lahner; Balasubramaniam Muthukumar; Monica Borghi; Joe Morrissey; Mary Lou Guerinot; David E Salt
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-12       Impact factor: 11.205

4.  Quantitative proteomic analysis of mitochondria in aging PS-1 transgenic mice.

Authors:  You-Jun Fu; Shuling Xiong; Mark A Lovell; Bert C Lynn
Journal:  Cell Mol Neurobiol       Date:  2009-02-25       Impact factor: 5.046

Review 5.  The validity of biomarkers as surrogate endpoints in Alzheimer's disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES).

Authors:  C C Gispen-de Wied; M Kritsidima; A J A Elferink
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

6.  S100A7, a novel Alzheimer's disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10.

Authors:  Weiping Qin; Lap Ho; Jun Wang; Elaine Peskind; Giulio Maria Pasinetti
Journal:  PLoS One       Date:  2009-01-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.